Provided by Tiger Trade Technology Pte. Ltd.

Instil Bio, Inc.

6.90
+0.01500.22%
Post-market: 6.900.00000.00%16:10 EDT
Volume:7K
Turnover:50.30K
Market Cap:46.80M
PE:-1.54
High:7.00
Open:6.89
Low:6.85
Close:6.89
52wk High:21.98
52wk Low:5.67
Shares:6.78M
Float Shares:3.66M
Volume Ratio:0.46
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4688
EPS(LYR):-10.7032
ROE:-25.33%
ROA:-10.77%
PB:0.44
PE(LYR):-0.64

Loading ...

Instil Bio shareholders ratify RSM US LLP as auditor for 2026

Reuters
·
Jun 12

Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

GlobeNewswire
·
Jun 04

TIL Enviro Sets 2026 AGM to Approve Results, Board Changes and Share Issue Mandate

TIPRANKS
·
May 29

Allogene names Zachary Roberts CEO, succeeding David Chang effective July 1, 2026

Reuters
·
May 29

Can Iovance (IOVA) Turn Early Amtagvi Data and Manufacturing Tweaks into a Durable Advantage?

Simply Wall St.
·
May 22

Iovance Biotherapeutics to Present at Upcoming Conference

GlobeNewswire
·
May 21

Iovance’s Terminated TIL Study Reshapes Expectations for Solid-Tumor Growth

TIPRANKS
·
May 16

Instil Bio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 15

Instil Bio Q1 Adj. EPS $(0.32) Beats $(0.59) Estimate

Benzinga Earnings
·
May 15

Instil Bio Q1 FY26 net loss narrows to $4.2 million from year-earlier $28.2 million

Reuters
·
May 15

Instil Bio Inc - Q1 2026 Non-Gaap Net Loss per Share $0.32

THOMSON REUTERS
·
May 15

Instil Bio Inc - Cash Position of $74.7 Mln as of March 31, 2026 to Fund Operations Beyond 2027

THOMSON REUTERS
·
May 15

Instil Bio Q1 Basic EPS USD -0.62

THOMSON REUTERS
·
May 15

Press Release: Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
May 15

Instil Bio Inc expected to post a loss of 59 cents a share - Earnings Preview

Reuters
·
May 09

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

GlobeNewswire
·
May 07

TIL Confirms No Deviation in Use of Rs 60 Crore Warrant Proceeds

TIPRANKS
·
May 02

Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026

GlobeNewswire
·
Apr 27

Instil Bio announces annual shareholder meeting

Reuters
·
Apr 25

Press Release: Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement

Dow Jones
·
Apr 15